Cargando…

Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients

BACKGROUND: Cancer pain is a common symptom in cancer patients. However, few reports have evaluated the effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients. The aim of this retrospective study is to reveal the effect of baseline cancer pain on the prognosis of lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Huan, Wei, Jingwen, Sun, Wei, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482640/
https://www.ncbi.nlm.nih.gov/pubmed/37691656
http://dx.doi.org/10.21037/jtd-23-375
_version_ 1785102215678001152
author Zhou, Huan
Wei, Jingwen
Sun, Wei
Song, Zhengbo
author_facet Zhou, Huan
Wei, Jingwen
Sun, Wei
Song, Zhengbo
author_sort Zhou, Huan
collection PubMed
description BACKGROUND: Cancer pain is a common symptom in cancer patients. However, few reports have evaluated the effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients. The aim of this retrospective study is to reveal the effect of baseline cancer pain on the prognosis of lung cancer patients receiving immunotherapy. METHODS: We retrospectively reviewed the medical records of lung cancer patients who received immunotherapy at Zhejiang Cancer Hospital and were included 280 patients with or without baseline cancer pain. Propensity score matching (PSM) was used to minimize potential selection bias. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier estimation and log-rank tests. Cox proportional hazard regression analysis was performed to identify factors associated with survival independence. RESULTS: The median PFS and OS of the patients with baseline cancer pain were significantly shorter than that of patients without baseline cancer pain (PFS: 3.1 vs. 6.5 months, P=0.001; OS: 16.5 vs. 31.2 months, P<0.001). PSM also included 27 patients with or without breakthrough pain. Patients with breakthrough pain had significantly shorter median PFS and OS than those without breakthrough pain (PFS: 1.9 vs. 4.2 months, P=0.001; OS: 9.9 vs. 18.7 months, P=0.012). Cox analysis results implicated breakthrough pain as an independent prognostic factor for immunotherapy. CONCLUSIONS: Baseline cancer pain is a negative prognostic factor for lung cancer patients receiving immunotherapy. Patients with baseline cancer pain may have a worse survival prognosis if they develop breakthrough pain.
format Online
Article
Text
id pubmed-10482640
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-104826402023-09-08 Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients Zhou, Huan Wei, Jingwen Sun, Wei Song, Zhengbo J Thorac Dis Original Article BACKGROUND: Cancer pain is a common symptom in cancer patients. However, few reports have evaluated the effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients. The aim of this retrospective study is to reveal the effect of baseline cancer pain on the prognosis of lung cancer patients receiving immunotherapy. METHODS: We retrospectively reviewed the medical records of lung cancer patients who received immunotherapy at Zhejiang Cancer Hospital and were included 280 patients with or without baseline cancer pain. Propensity score matching (PSM) was used to minimize potential selection bias. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier estimation and log-rank tests. Cox proportional hazard regression analysis was performed to identify factors associated with survival independence. RESULTS: The median PFS and OS of the patients with baseline cancer pain were significantly shorter than that of patients without baseline cancer pain (PFS: 3.1 vs. 6.5 months, P=0.001; OS: 16.5 vs. 31.2 months, P<0.001). PSM also included 27 patients with or without breakthrough pain. Patients with breakthrough pain had significantly shorter median PFS and OS than those without breakthrough pain (PFS: 1.9 vs. 4.2 months, P=0.001; OS: 9.9 vs. 18.7 months, P=0.012). Cox analysis results implicated breakthrough pain as an independent prognostic factor for immunotherapy. CONCLUSIONS: Baseline cancer pain is a negative prognostic factor for lung cancer patients receiving immunotherapy. Patients with baseline cancer pain may have a worse survival prognosis if they develop breakthrough pain. AME Publishing Company 2023-07-25 2023-08-31 /pmc/articles/PMC10482640/ /pubmed/37691656 http://dx.doi.org/10.21037/jtd-23-375 Text en 2023 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zhou, Huan
Wei, Jingwen
Sun, Wei
Song, Zhengbo
Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients
title Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients
title_full Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients
title_fullStr Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients
title_full_unstemmed Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients
title_short Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients
title_sort effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482640/
https://www.ncbi.nlm.nih.gov/pubmed/37691656
http://dx.doi.org/10.21037/jtd-23-375
work_keys_str_mv AT zhouhuan effectofbaselinecancerpainontheefficacyofimmunotherapyinlungcancerpatients
AT weijingwen effectofbaselinecancerpainontheefficacyofimmunotherapyinlungcancerpatients
AT sunwei effectofbaselinecancerpainontheefficacyofimmunotherapyinlungcancerpatients
AT songzhengbo effectofbaselinecancerpainontheefficacyofimmunotherapyinlungcancerpatients